Lincoln Pharmaceuticals Ltd
Tue 29/04/2025,15:53:21 | NSE : LINCOLN
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 595.60
Previous Close
₹ 588.60
Volume
28939
Mkt Cap ( Rs. Cr)
₹1167.03
High
₹ 605.20
Low
₹ 576.90
52 Week High
₹ 979.50
52 Week Low
₹ 499.00
Book Value Per Share
₹ 319.16
Dividend Yield
0.30
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Lincoln Pharmaceuticals Ltd
Your Vote -
Buy
79.17%
Hold
16.67%
Sell
4.17%
79.17%
24 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
582.65
170
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
170
Option Chain
Analyzes market sentiment, predicts Lincoln Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Lincoln Pharmace - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Lincoln Pharmace - Updates
-
Lincoln Pharmace - Disclosure under SEBI Takeover Regulations
-
Lincoln Pharmace has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Lincoln Pharmace - Disclosure under SEBI Takeover Regulations
-
Lincoln Pharmace - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Lincoln Pharmace - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Lincoln Pharmace - General Updates
-
Lincoln Pharmace - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015.
-
Lincoln Pharmace - Trading Window-XBRL
-
Lincoln Pharmace - Trading Window
-
Lincoln Pharmace - Reply to Clarification- Financial results
-
Lincoln Pharmace - Clarification - Financial Results
-
Lincoln Pharmace - Copy of Newspaper Publication
-
Lincoln Pharmace - Integrated Filing- Financial
-
Lincoln Pharmace - Financial Result Updates
-
Lincoln Pharmace - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING
-
Lincoln Pharmace - Integrated Filing (Financial)
-
Lincoln Pharmace - UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024\r\n
-
Lincoln Pharmace Q3 net profit down 25.93% at Rs 20.77 cr
-
Lincoln Pharmace - Board Meeting Intimation
-
Lincoln Pharmace - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Con
-
Lincoln Pharma
-
Lincoln Pharmaceuticals gets nod from Australian Regulator, TGA
-
Lincoln Pharmaceuticals plans to launch Cephalosporin products soon
-
Lincoln Pharma launches Vitamin C+ Zinc tablets
-
Lincoln Pharma gets EU GMP approval
-
Lincoln Pharma receives nod to manufacture Hydroxychloroquine
Key fundamentals
Evaluate the intrinsic value of Lincoln Pharmaceuticals Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 593.9027 | 504.4716 | 434.921 | 365.0977 | 308.8478 |
Liabilities | 593.9027 | 504.4716 | 434.921 | 365.0977 | 308.8478 |
Equity | 20.0297 | 20.0297 | 20.0297 | 20 | 20 |
Gross Profit | 99.9074 | 89.1668 | 95.4702 | 81.35 | 59.3688 |
Net Profit | 93.3049 | 72.8994 | 69.355 | 60.4061 | 49.5636 |
Cash From Operating Activities | 63.2445 | 39.1562 | 76.1831 | 71.41 | 70.71 |
NPM(%) | 16.07 | 14.28 | 14.69 | 14.62 | 13.17 |
Revenue | 580.5496 | 510.3088 | 472.0789 | 413.0552 | 376.0883 |
Expenses | 480.6422 | 421.142 | 376.6087 | 331.7052 | 316.7195 |
ROE(%) | 14.59 | 11.4 | 10.84 | 9.44 | 7.75 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
13 Sep 2024 | 1.8 | 18 | 0.31 | 572.75 |
15 Sep 2023 | 1.5 | 15 | 0.31 | 394.4 |
15 Sep 2022 | 1.5 | 15 | 0.31 | 283.8 |
16 Sep 2021 | 1.5 | 15 | 0.31 | 296.25 |
05 Mar 2020 | 1.5 | 15 | 0.31 | 177.55 |
19 Sep 2019 | 1.5 | 15 | 0.31 | 180.75 |
19 Sep 2018 | 1.5 | 15 | 0.31 | 216.05 |
21 Sep 2017 | 1.2 | 12 | 0.31 | 187.55 |
23 Sep 2016 | 1 | 10 | 0.31 | 150 |
Peers
Other companies within the same industry or sector that are comparable to Lincoln Pharmaceuticals Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 840.85 | 0.23 | 11.87 | 335.93 | 1321.50 | 1.37 |
Lotus Eye Hospital and Institute Ltd | 81.36 | 2.94 | 339.00 | 1224.07 | 14.01 | 0.61 |
Vaishali Pharma Ltd | 13.72 | -0.15 | 457.33 | 630.93 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 693.05 | -1.61 | 0.00 | 1154.19 | -687.11 | 0.00 |
Company Info
The Company was incorporated as a public limited company by converting partnership concern M/s. Lincoln Pharmaceuticals under Part IX of the Companies Act 1956. M/s.Lincoln Pharmaceuticals was established as a partnership firm on 18th January 1979 with Mr. Rajni G. Patel, Mr. Hasmukhbhai I.Patel, Mrs. Hansaben A.Patel, Mrs. Jivtiben C.Patel, Mrs. Jiviben T.Patel and Mrs. Lilaben T. Patel as partners, with its main object of manufacturing pharmaceutical formulations. The business was started in Naroda G.I.D.C estate. Further on 9.12.81, Mr.Mihir V. Patel, Mr.Maheshbhai M.Patel, Mr.Yogeshkumar I. Patel and Mrs.Madhuben V.Patel were admitted as Partners. The firm was carrying on its business by getting its products manufactured on Loan and Licence Basis from 1979 to 1982. All the partners decided and agreed vide resolution dated 30.10.94 that all members of Co-partnership should register the said firm as public limited company for sake of smooth working, better and effective management and improvement and advancement of business. It was also decided as per the said resolution that such company should carry Out and continue the existing business of the firm. As a result, an the incorporation of the Company on 20th January 1995, all the properties of the firm (movable & immovable) and all the liabilities of the firm 55 an the closing of the business of the day proceeding the date of incorporation of the Company vested in the Company. Since, date of incorporation of the Company i.e, 20th January 1995, all the assets and liabilities, aforesaid as on 19th January 1995, vested in the Company. Company is carrying on running business of erstwhile M/s. Lincoln Pharmaceuticals having its formulations production facilities at Naroda, GIDC, Ahmedabad, Gujarat, of manufacturing tablets, capsules, liquid and powder syrups and ointments. Company is also getting its products manufactured on "Loan and License" basis from other manufacturers to meet the demand of small volume parenterals. The Company has now decided to establish modern formulations manufacturing plant at Village: Khatraj. Tal:Kalol, Olaf. Mehsana in Gujarat to manufacture small volume parenterals like Dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of manufacturing tablets, capsules, liquid/powder syrups and ointment and also to establish fully equipped laboratory to undertake in house testing of its products for better quality control and give thrust on Research and Development. Company has already acquired N.A land Adm: 8833 Sq. Mtrs. and is in the process of acquiring further land adm. aprox.11,170 Sq.Mtrs. Company has given advance for booking cement and steel and are preparing to commence construction of factory building at new site. Company has identified all plant and machineries and has also given advance to major plant & machinery suppliers far those machineries which has longer delivery period, so as to implement the project an time. The company has existing manufacturing facilities at Naroda and if is already selling its products all over India and is having thrust in the markets of Gujarat, Rajasthan, Andhra Pradesh, Bihar and Jammu. 2000 - The company has signed agreements with NSDL & CDSL for dematerialisation. 2003 - The Joint Director of General Govt of India has given the certificate of recognition of Export House to the company. -Lincoln Pharmaceuticals introduces AIDS Drugs -Launched US FDA approved drug Gatifloxacin. -Launched PROLIN - NATURAL -Lincoln Pharmaceuticals Ltd has informed that it has launched a new drug under the brand name of 'Namsafe'. - Lincoln Pharmaceuticals Ltd has delists equity shares from Delhi Stock Exchange Association Ltd 2005 -Lincoln Pharmaceuticals secures export order from England, UK 2006 -Lincoln Pharma introduces Nozzled Liquid formulations -Lincoln Pharmaceuticals secures order from Republic Democratic of Congo -Lincoln Pharmaceuticals introduces Vivian Roll On in Novel Drug Delivery System -The Company has signed agreement with Russian firm M/s. Fortune Impex Ltd for marketing Company's manufactured products in Russia. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2008 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2009 -Lincoln Pharmaceuticals has incorporated new Company namely M/s. Zullinc Healthcare Ltd as wholly owned subsidiary Company of Lincoln Pharmaceuticals Ltd. -Company has Consolidates its Face value of Shares from Rs 2 to Rs 10 2010 -Lincoln Pharmaceuticals Ltd. gains market share with technologically advanced Collagen Bio-tech products 2011 -Lincoln Pharmaceuticals wins patent for a Novel Nasal Drug delivery system introduces India's first Nasal Spray treatment for Vomiting. -Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain -Lincoln Pharmaceuticals Ltd launches Antimalarial drug 'ARH 1' developed with innovative dose optimization technology, for the first time in the world. -Lincoln Pharmaceuticals Ltd. launches Ayurvedic Product 'ISL Granules' to serve mother and child healthcare segment. -Lincoln Pharmaceuticals has acquired / purchased 62 Lacs equity shares of M/s. Lincoln Parenteral Ltd and by virtue of said acquisition / purchase of equity share, M/s. Lincoln Parenteral Ltd has become subsidiary Company 2012 -Lincoln Pharmaceuticals has recommended the payment of Dividend @ Rs. 0.60/- per equity share (6%) on face value of Rs. 10/- each 2013 -Lincoln Pharmaceuticals has recommended the payment of Dividend of Rs. 0.60 (@ 6%) per equity share of face value Rs. 10/- each. 2014 -"Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable". -Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company. 2015 -The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex. 2016 -"Lincoln Pharmaceuticals launches Vaginal Spray for "FIRST TIME IN INDIA". 2020 - Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs. =The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant. 2021 -The company eceived approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.
The Company was incorporated as a public limited company by converting partnership concern M/s. Lincoln Pharmaceuticals under Part IX of the Companies Act 1956. M/s.Lincoln Pharmaceuticals was established as a partnership firm on 18th January 1979 with Mr. Rajni G. Patel, Mr. Hasmukhbhai I.Patel, Mrs. Hansaben A.Patel, Mrs. Jivtiben C.Patel, Mrs. Jiviben T.Patel and Mrs. Lilaben T. Patel as partners, with its main object of manufacturing pharmaceutical formulations. The business was started in Naroda G.I.D.C estate. Further on 9.12.81, Mr.Mihir V. Patel, Mr.Maheshbhai M.Patel, Mr.Yogeshkumar I. Patel and Mrs.Madhuben V.Patel were admitted as Partners. The firm was carrying on its business by getting its products manufactured on Loan and Licence Basis from 1979 to 1982. All the partners decided and agreed vide resolution dated 30.10.94 that all members of Co-partnership should register the said firm as public limited company for sake of smooth working, better and effective management and improvement and advancement of business. It was also decided as per the said resolution that such company should carry Out and continue the existing business of the firm. As a result, an the incorporation of the Company on 20th January 1995, all the properties of the firm (movable & immovable) and all the liabilities of the firm 55 an the closing of the business of the day proceeding the date of incorporation of the Company vested in the Company. Since, date of incorporation of the Company i.e, 20th January 1995, all the assets and liabilities, aforesaid as on 19th January 1995, vested in the Company. Company is carrying on running business of erstwhile M/s. Lincoln Pharmaceuticals having its formulations production facilities at Naroda, GIDC, Ahmedabad, Gujarat, of manufacturing tablets, capsules, liquid and powder syrups and ointments. Company is also getting its products manufactured on "Loan and License" basis from other manufacturers to meet the demand of small volume parenterals. The Company has now decided to establish modern formulations manufacturing plant at Village: Khatraj. Tal:Kalol, Olaf. Mehsana in Gujarat to manufacture small volume parenterals like Dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of manufacturing tablets, capsules, liquid/powder syrups and ointment and also to establish fully equipped laboratory to undertake in house testing of its products for better quality control and give thrust on Research and Development. Company has already acquired N.A land Adm: 8833 Sq. Mtrs. and is in the process of acquiring further land adm. aprox.11,170 Sq.Mtrs. Company has given advance for booking cement and steel and are preparing to commence construction of factory building at new site. Company has identified all plant and machineries and has also given advance to major plant & machinery suppliers far those machineries which has longer delivery period, so as to implement the project an time. The company has existing manufacturing facilities at Naroda and if is already selling its products all over India and is having thrust in the markets of Gujarat, Rajasthan, Andhra Pradesh, Bihar and Jammu. 2000 - The company has signed agreements with NSDL & CDSL for dematerialisation. 2003 - The Joint Director of General Govt of India has given the certificate of recognition of Export House to the company. -Lincoln Pharmaceuticals introduces AIDS Drugs -Launched US FDA approved drug Gatifloxacin. -Launched PROLIN - NATURAL -Lincoln Pharmaceuticals Ltd has informed that it has launched a new drug under the brand name of 'Namsafe'. - Lincoln Pharmaceuticals Ltd has delists equity shares from Delhi Stock Exchange Association Ltd 2005 -Lincoln Pharmaceuticals secures export order from England, UK 2006 -Lincoln Pharma introduces Nozzled Liquid formulations -Lincoln Pharmaceuticals secures order from Republic Democratic of Congo -Lincoln Pharmaceuticals introduces Vivian Roll On in Novel Drug Delivery System -The Company has signed agreement with Russian firm M/s. Fortune Impex Ltd for marketing Company's manufactured products in Russia. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2008 -Lincoln Pharmaceuticals recommends final Dividend @ 12% 2009 -Lincoln Pharmaceuticals has incorporated new Company namely M/s. Zullinc Healthcare Ltd as wholly owned subsidiary Company of Lincoln Pharmaceuticals Ltd. -Company has Consolidates its Face value of Shares from Rs 2 to Rs 10 2010 -Lincoln Pharmaceuticals Ltd. gains market share with technologically advanced Collagen Bio-tech products 2011 -Lincoln Pharmaceuticals wins patent for a Novel Nasal Drug delivery system introduces India's first Nasal Spray treatment for Vomiting. -Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain -Lincoln Pharmaceuticals Ltd launches Antimalarial drug 'ARH 1' developed with innovative dose optimization technology, for the first time in the world. -Lincoln Pharmaceuticals Ltd. launches Ayurvedic Product 'ISL Granules' to serve mother and child healthcare segment. -Lincoln Pharmaceuticals has acquired / purchased 62 Lacs equity shares of M/s. Lincoln Parenteral Ltd and by virtue of said acquisition / purchase of equity share, M/s. Lincoln Parenteral Ltd has become subsidiary Company 2012 -Lincoln Pharmaceuticals has recommended the payment of Dividend @ Rs. 0.60/- per equity share (6%) on face value of Rs. 10/- each 2013 -Lincoln Pharmaceuticals has recommended the payment of Dividend of Rs. 0.60 (@ 6%) per equity share of face value Rs. 10/- each. 2014 -"Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable". -Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company. 2015 -The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex. 2016 -"Lincoln Pharmaceuticals launches Vaginal Spray for "FIRST TIME IN INDIA". 2020 - Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs. =The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant. 2021 -The company eceived approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.
Read More
Parent Organisation
Lincoln Pharmaceuticals Ltd.
Founded
20/01/1995
Managing Director
Mr.Mahendra G Patel
NSE Symbol
LINCOLNEQ
FAQ
The current price of Lincoln Pharmaceuticals Ltd is ₹ 582.65.
The 52-week high for Lincoln Pharmaceuticals Ltd is ₹ 605.20 and the 52-week low is ₹ 576.90.
The market capitalization of Lincoln Pharmaceuticals Ltd is currently ₹ 1167.03. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Lincoln Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Lincoln Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Lincoln Pharmaceuticals Ltd shares.
The CEO of Lincoln Pharmaceuticals Ltd is Mr.Mahendra G Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.